Novartis Groupe France S.A.

Novartis Groupe France S.A. currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of emissions figures. However, it is important to note that Novartis Groupe France S.A. is a current subsidiary of Novartis AG, which provides a framework for its climate commitments and initiatives.

As part of its corporate family relationship, Novartis Groupe France S.A. inherits climate-related targets and initiatives from Novartis AG. This includes commitments to the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are cascaded from Novartis AG. These initiatives reflect a broader commitment to reducing carbon emissions and enhancing sustainability practices across the organisation.

While specific reduction targets for Novartis Groupe France S.A. are not detailed, the overarching goals set by Novartis AG indicate a strong commitment to addressing climate change and reducing environmental impact. The company is actively engaged in various sustainability initiatives aimed at achieving significant reductions in carbon emissions, although specific metrics and timelines are not provided in the current data.

In summary, while Novartis Groupe France S.A. does not present specific emissions data or reduction targets, it aligns with the climate commitments and initiatives established by its parent company, Novartis AG, demonstrating a commitment to sustainability and climate action within the pharmaceutical industry.